Inclusion Criteria:

- No age limit

- Declaration of informed consent signed by patient or legal guardian

- Patients with a solid tumour or with a malignant haematological tumour

- Patients for whom cytotoxic chemotherapy is planned, irrespective of cycle

- Patients who are due to undergo, or who should undergo, (primary or secondary)
prophylactic treatment using NivestimTM, either to shorten the duration of a
neutropenia or to prevent the occurrence of chemotherapy induced FN.

Exclusion Criteria:

- Patients with chronic myeloid leukaemia (CML) or with myelodysplastic

- Syndrome (MDS)

- Patients who are hypersensitive to the active substance or to one of the

- Excipients of NivestimTM

- Patients not undergoing chemotherapy

- Patients being treated curatively with G-CSF